Alembic Pharmaceuticals Ltd. (APLLTD) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 807696, "name": "Alembic Pharma", "stock_name": "Alembic Pharma", "full_name": "Alembic Pharmaceuticals Ltd.", "name_url": "stocks-analysis/alembic-pharma", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "739.90", "chg": 5.25, "chgp": "0.71%", "dir": 1, "prev_price": "734.65", "mcapval": "14,543.71 Cr", "mcap": "Small Cap", "scripcode": 533573, "symbol": "APLLTD", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE901L01018", "curr_date": "Jun 12, 10:08 AM", "curr_time": "10:25 AM", "last_traded_at": "Jun 12, 10:08 AM IST", "bse_nse_vol": "16.62 k", "exc_status": "Active", "traded_date": "Jun 12, 2026", "traded_date_str": "2026 06 12", "score": "", "scoreText": "", "Live": 0, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alembic-pharma-807696-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-4030648", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AlembicPharmace_mojoScore_4030648.png", "date": "2026-06-02 10:10:19", "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Alembic Pharmaceuticals Ltd. Technical Momentum Shifts Amid Bearish Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-ltd-technical-momentum-shifts-amid-bearish-signals-4029622", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/AlembicPharmace_technicaldot_4029622.png", "date": "2026-06-02 08:06:53", "description": "Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s recent downgrade from a Hold to a Sell rating reflects deteriorating price action and weakening market sentiment, underscored by a 2.21% decline in the latest trading session and a broader negative trend across weekly and monthly technical parameters." }, { "title": "Alembic Pharmaceuticals Declines 3.73%: Mixed Technical Signals Shape Weekly Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-declines-373-mixed-technical-signals-shape-weekly-performance-4008468", "imagepath": "", "date": "2026-05-23 15:05:44", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>18 May:</strong> Intraday low hit amid significant price pressure (Rs.723.95)</p>\n <p><strong>18 May:</strong> Technical momentum shifts to mildly bearish stance</p>\n <p><strong>19 May:</strong> Recovery attempt with 3.85% gain</p>\n <p><strong>22 May:</strong> Week closes at Rs.755.45, down 3.73%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.784.70</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.755.45</div><div class=\"stat..." }, { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-4004898", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AlembicPharmace_mojoScore_4004898.png", "date": "2026-05-22 10:10:40", "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance." }, { "title": "Alembic Pharmaceuticals Ltd. Hits Intraday Low Amid Price Pressure on 18 May 2026", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-ltd-hits-intraday-low-amid-price-pressure-on-18-may-2026-3996449", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AlembicPharmace_priceRelatedfactors_3996449.png", "date": "2026-05-18 09:51:02", "description": "Alembic Pharmaceuticals Ltd. experienced a notable decline today, hitting an intraday low of Rs 728, reflecting a sharp price pressure of -7.23% as the stock underperformed its sector and broader market indices amid a broadly bearish market environment." }, { "title": "Alembic Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-ltd-technical-momentum-shifts-amid-mixed-market-signals-3996053", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AlembicPharmace_technicaldot_3996053.png", "date": "2026-05-18 08:02:19", "description": "Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite mixed signals from key indicators such as MACD, RSI, and moving averages, the stock’s recent price action and volume patterns suggest a nuanced outlook for investors navigating the Pharmaceuticals & Biotechnology sector." }, { "title": "Are Alembic Pharmaceuticals Ltd. latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-alembic-pharmaceuticals-ltd-latest-results-good-or-bad-3995010", "imagepath": "", "date": "2026-05-16 19:25:25", "description": "Alembic Pharmaceuticals Ltd.'s latest financial results for Q4 FY26 present a complex picture of profitability and operational challenges. The company reported a net profit of ₹202.70 crores, reflecting a year-on-year growth of 29.20% compared to the same quarter last year, which is a notable improvement from a previous decline. However, this profit surge was significantly influenced by an unusual tax credit, which raises questions about the sustainability of this growth.\n\nOn the revenue front, Alembic Pharmaceuticals experienced a quarter-on-quarter decline of 1.52%, with net sales reaching ₹1,847.72 crores. This marks a slowdown in growth, as the company had previously reported a year-on-year growth of 16.66% in the same quarter last year. The operational efficiency metrics are concerning, with the operating margin dropping to 12.34%, the lowest in eight quarters, indicating mounting cost pressures and op..." }, { "title": "Alembic Pharmaceuticals Q4 FY26: Tax Reversal Masks Operational Weakness", "link": "https://www.marketsmojo.com/news/result-analysis/alembic-pharmaceuticals-q4-fy26-tax-reversal-masks-operational-weakness-3993458", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AlembicPharmace_quaterlyResult_3993458.png", "date": "2026-05-15 20:46:23", "description": "Alembic Pharmaceuticals Ltd. posted a consolidated net profit of ₹202.70 crores in Q4 FY26, marking a robust 52.44% quarter-on-quarter growth and 29.20% year-on-year expansion. However, this headline figure conceals a troubling operational reality—the company's profit surge was driven almost entirely by a tax reversal that resulted in a negative tax rate of 69.90%, whilst core business metrics deteriorated significantly. The stock currently trades at ₹784.70, down 29.17% from its 52-week high, reflecting investor concerns about the underlying business trajectory." }, { "title": "Alembic Pharmaceuticals Ltd. is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-ltd-is-rated-sell-3985369", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AlembicPharmace_mojoScore_3985369.png", "date": "2026-05-11 10:10:49", "description": "Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook." } ], "total": 5288, "sid": "807696", "stock_news_url": "https://www.marketsmojo.com/news/alembic-pharmaceuticals-807696" }, "announcements": [ { "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 26, 2019, titled \"Alembic Pharmaceuticals receives USFDA Final Approval for Silodosin Capsules, 4 mg and 8 mg.\".", "source": "NSE", "caption": "Alembic Pharmaceuticals Limited - Press Release", "datetime": "26-Nov-2019" }, { "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 22, 2019, titled \"Alembic Pharmaceuticals receives USFDA Approvals \".", "source": "NSE", "caption": "Alembic Pharmaceuticals Limited - Press Release", "datetime": "22-Nov-2019" }, { "details": "Alembic Pharmaceuticals Limited has informed the Exchange regarding Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ( Listing Regulations, 2015 )", "source": "NSE", "caption": "Alembic Pharmaceuticals Limited - Other General Purpose", "datetime": "14-Nov-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Alembic Pharmaceuticals Ltd. has declared <strong>550%</strong> dividend, ex-date: 29 Jul 25", "dt": "2025-07-29", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

18 May: Intraday low hit amid significant price pressure (Rs.723.95)

18 May: Technical momentum shifts to mildly bearish stance

19 May: Recovery attempt with 3.85% gain

22 May: Week closes at Rs.755.45, down 3.73%

Read full news article

Alembic Pharmaceuticals Ltd. is Rated Sell

2026-05-22 10:10:40

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Alembic Pharmaceuticals Ltd. Hits Intraday Low Amid Price Pressure on 18 May 2026

2026-05-18 09:51:02

Alembic Pharmaceuticals Ltd. experienced a notable decline today, hitting an intraday low of Rs 728, reflecting a sharp price pressure of -7.23% as the stock underperformed its sector and broader market indices amid a broadly bearish market environment.

Read full news article

Alembic Pharmaceuticals Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-05-18 08:02:19

Alembic Pharmaceuticals Ltd. has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite mixed signals from key indicators such as MACD, RSI, and moving averages, the stock’s recent price action and volume patterns suggest a nuanced outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Are Alembic Pharmaceuticals Ltd. latest results good or bad?

2026-05-16 19:25:25

Alembic Pharmaceuticals Ltd.'s latest financial results for Q4 FY26 present a complex picture of profitability and operational challenges. The company reported a net profit of ₹202.70 crores, reflecting a year-on-year growth of 29.20% compared to the same quarter last year, which is a notable improvement from a previous decline. However, this profit surge was significantly influenced by an unusual tax credit, which raises questions about the sustainability of this growth. On the revenue front, Alembic Pharmaceuticals experienced a quarter-on-quarter decline of 1.52%, with net sales reaching ₹1,847.72 crores. This marks a slowdown in growth, as the company had previously reported a year-on-year growth of 16.66% in the same quarter last year. The operational efficiency metrics are concerning, with the operating margin dropping to 12.34%, the lowest in eight quarters, indicating mounting cost pressures and op...

Read full news article

Alembic Pharmaceuticals Q4 FY26: Tax Reversal Masks Operational Weakness

2026-05-15 20:46:23

Alembic Pharmaceuticals Ltd. posted a consolidated net profit of ₹202.70 crores in Q4 FY26, marking a robust 52.44% quarter-on-quarter growth and 29.20% year-on-year expansion. However, this headline figure conceals a troubling operational reality—the company's profit surge was driven almost entirely by a tax reversal that resulted in a negative tax rate of 69.90%, whilst core business metrics deteriorated significantly. The stock currently trades at ₹784.70, down 29.17% from its 52-week high, reflecting investor concerns about the underlying business trajectory.

Read full news article

Alembic Pharmaceuticals Ltd. is Rated Sell

2026-05-11 10:10:49

Alembic Pharmaceuticals Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article